Skip to content

Beyond Donor-Specific Antibodies: Molecular Characterization of Antibody-Mediated Rejection Using Tissue-Based Transcriptomics in Heart Transplantation.

Aug 2026 · The Journal of Heart and Lung Transplantation · 1 citation · 51 references
Medicine

TL;DR

Molecular ABMR exhibited similar profiles regardless of HLA-DSA status and, within DSA-negative cases, non-HLA antibody status, and may complement conventional evaluation by refining ABMR phenotyping.

Abstract

Background

Antibody-mediated rejection (AMR) contributes to graft dysfunction after heart transplantation, yet histopathology and circulating donor-specific antibodies (DSA) may incompletely capture intragraft biology. We characterized molecular ABMR by HLA-DSA status and, within DSA-negative cases, non-HLA antibody status.

Methods

We analyzed 579 for-cause endomyocardial biopsies with paired Molecular Microscope Diagnostic System (MMDx) and histopathology. Molecular scores, transcripts, donor-derived cell-free DNA (dd-cfDNA), and gene-expression profiling (GEP) were compared using patient-clustered models with false-discovery-rate correction. Multivariable Cox models evaluated a 2-year composite of death, retransplantation, graft dysfunction (LVEF<50%), or subsequent histologic rejection (ACR≥1B/2R or pAMR≥1).

Results

MMDx-defined ABMR was present in 83 biopsies (14.3%); 30 (36.1%) were DSA-negative. DSA-negative and DSA-positive ABMR had similar ABMR probabilities (0.66 vs 0.66), global rejection scores, dd-cfDNA (0.83% vs 0.63%), GEP (35 vs 33), and transcriptomic profiles. Within DSA-negative ABMR, non-HLA antibodies were detected in 20/30 (66.7%) and associated with higher ABMR probability (0.69 vs 0.63; P=0.041), dd-cfDNA (0.91% vs 0.62%; P=0.048), GEP (35 vs 33; P=0.019), and greater endothelial, ABMR/NK-cell, interferon-γ, and injury-related transcript activation. Histologic-molecular agreement was limited (κ=0.14); 70/83 molecular ABMR biopsies lacked histologic pAMR. In joint models, molecular ABMR, but not pAMR, was associated with higher dd-cfDNA (b=0.38%, P=0.039). Conversely, histologic pAMR independently predicted the composite outcome (adjusted HR 2.68, 95% CI 1.34-5.35; P=0.005), whereas molecular ABMR did not (adjusted HR 0.93, 95% CI 0.56-1.56; P=0.795).

Conclusions

Molecular ABMR exhibited similar profiles regardless of HLA-DSA status. Non-HLA antibodies identified greater activation and dd-cfDNA levels within DSA-negative ABMR. Molecular assessment may complement conventional evaluation by refining ABMR phenotyping.

View source

Similar papers

Review Open access Sep 2026

Advances in antibody-mediated rejection of renal allografts

This review summarizes current concepts in AMR pathogenesis, diagnosis, and emerging therapy, using phenotype-guided assessment to separate expert-consensus practice from randomized evidence, observational experience, and experimental interventions.

Bi-Du Song, Jun-Jie Sun, Chao Hu et al. · 0 citations
Open access Sep 2026

Diagnostic Performance of Donor-derived Cell-free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation.

BACKGROUND Accurate differentiation of acute rejection (AR) from other causes of graft dysfunction after liver transplantation remains challenging in real-world clinical practice. Although donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising non-invasive biomarker of graft injury, its specificity may be li...

Xue-Chun Zhao, Bo Yang, Hong-Mei Jiang et al. · 0 citations
Open access Sep 2026

Management of donor-specific antibodies in allogeneic hematopoietic cell transplantation: A retrospective single-center case-control study

Donor-specific antibodies (DSA) are preformed recipient antibodies directed against donor HLA antigens, most frequently observed in haploidentical or mismatched allogeneic hematopoietic cell transplantation (HCT). DSA assessed by multiplexed bead-based immunoassays at mean fluorescence intensity (MFI) values >1 000 are...

Lennart Harland, Semian L. Schüch, Sarah Katzenstein et al. · 0 citations
Oct 2026

NK cell missing self in microvascular inflammation with and without donor-specific antibodies.

BACKGROUND AND HYPOTHESIS Microvascular inflammation (MVI), a histological hallmark of antibody-mediated rejection (AMR), is typically associated with donor-specific antibodies (DSA), but can also occur in their absence. Evidence implicates Natural Killer (NK) cells in DSA-negative MVI, although the mechanisms underlyi...

B. Mordà, A. Akifova, Matthias Diebold et al. · 0 citations
Open access Oct 2026

Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population

Endomyocardial biopsy (EMB) is the gold standard for diagnosing post-heart transplant acute rejection (AR) but is invasive. Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker, yet thresholds for Asian recipients remain undefined. This prospective study enrolled 80 patients, with 299 dd-cfDNA sp...

Shan-Shan Zheng, Sheng Liu, Zhi-Yuan Zhu et al. · 0 citations
Review Aug 2026

Donor-derived cell-free DNA in liver transplantation: Promise, limitations, and future directions.

Donor-derived cell-free DNA (dd-cfDNA) is an emerging non-invasive biomarker with growing potential for monitoring graft health and detecting rejection after liver transplantation. Several studies suggest that dd-cfDNA may provide a sensitive approach for assessing graft injury and immune-mediated rejection, although i...

Zahra Beyzaei, Melika Abdollahi, Kiana Ghafourian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.